A Phase 2 interventional study of ETC-1002 and Placebo in Dyslipidemia, sponsored by Esperion Therapeutics, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-17.
Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 349 studies in Dyslipidemias with a site in United States — 23 open to participants now, 34 under way, 6 of them phase 3. Dyslipidemias · United States.
Among the 349 studies in Dyslipidemias with a site in United States, this one is the 124th largest by enrollment of the 316 interventional ones that give a count, is one of 18 that started in 2010, is one of 66 in phase 2, and was the 143rd registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →23 of the 349 studies in Dyslipidemias with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Connecticut · Sites in United States
Ages 18–64
University of Georgia · Sites in United States
Ages 25–75 · Healthy volunteers
AstraZeneca · Sites in United States
Ages 18–70
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
349 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 75 · Phase 3 76 · Phase 4 23
First in 1976; this study’s year is marked. 18 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 177 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 105 across the 316 interventional studies, 140 across the 31 observational. Of the 299 that completed or were terminated, 125 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
170 of 349 have an industry lead sponsor. The 10 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Esperion Therapeutics, Inc. has 2 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
13 of the studies in Dyslipidemias with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06496243NewAmsterdam PharmaImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | 2026-11 |
| NCT06382298University of GeorgiaCottonseed Oil Versus Matched PUFA Effects | 2026-12 |
| NCT06300450Brigham and Women's HospitalRandomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy | 2026-12-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 349 studies in Dyslipidemias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.
Major Inclusion Criteria:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with hypercholesterolemia and normal triglycerides
Drug: ETC-1002
Subjects with hypercholesterolemia and normal triglycerides
Drug: ETC-1002
Subjects with hypercholesterolemia and normal triglycerides
Drug: ETC-1002
Subjects with hypercholesterolemia and normal triglycerides
Drug: Placebo
Subjects with hypercholesterolemia and elevated triglycerides
Drug: ETC-1002
Subjects with hypercholesterolemia and elevated triglycerides
Drug: ETC-1002
Subjects with hypercholesterolemia and elevated triglycerides
Drug: ETC-1002
Subjects with hypercholesterolemia and elevated triglycerides
Drug: Placebo
ETC-1002 daily for 12 weeks
Placebo daily for 12 weeks
Percent Change From Baseline to Week 12 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. Least square (LS) mean percent change from Baseline to Week 12 was based on an analysis of covariance (ANCOVA) model with effects of treatment and triglyceride (TG) stratum and Baseline value as a covariate. Missing LDL-C values at Week 12 were imputed using the last observation carried forward (LOCF) procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Percent Change From Baseline to Week 12 in LDL-C by Triglyceride (TG) Stratum
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and center and Baseline value as a covariate. Missing LDL-C values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Percent Change From Baseline to Week 12 in TG
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing TG values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Percent Change From Baseline to Week 12 in High-Density Lipoprotein-Cholesterol (HDL-C)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing HDL-C values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Percent Change From Baseline to Week 12 in Non-HDL-C
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing non-HDL-C values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing TC values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Percent Change From Baseline to Week 12 in Apolipoprotein B (ApoB)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing ApoB values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Percent Change From Baseline to Week 12 in Apolipoprotein AI (ApoAI)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing ApoAI values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Percent Change From Baseline to Week 12 in Lipoprotein (a)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing Lipoprotein (a) values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Percent Change From Baseline to Week 12 in Free Fatty Acids (FFA)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing FFA values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (hsCRP)
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the value from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing hsCRP values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Percent Change From Baseline to Week 12 in Total LDL Particles
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Percent Change From Baseline to Week 12 in Total HDL Particles
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
Time frame: Baseline; 12 weeks
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as adverse events (AEs) that began or worsened in severity after the first dose of study medication, occurring up to 30 days after the last dose of study medication.
Time frame: up to 12 weeks
Number of Participants With Clinically Significant Physical Examination Findings
Clinical significance was determined by the investigator.
Time frame: up to 12 weeks
Number of Participants With Clinically Important Changes From Baseline in Vital Sign Values
Clinical importance was determined by the investigator.
Time frame: Baseline; up to 12 weeks
Number of Participants With Clinically Important Changes From Baseline in Electrocardiogram Values
Clinical importance was determined by the investigator.
Time frame: Baseline; up to 12 weeks
Number of Participants With the Indicated Abnormal Laboratory Parameter Values at Week 12
Laboratory abnormalities are laboratory values that are outside the normal range.
Time frame: Week 12
A total of 177 participants were enrolled and treated across 11 study sites in the United States.
| Milestone | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Started | 45 | 44 | 44 | 44 |
| Completed | 38 | 38 | 38 | 37 |
| Not completed | 7 | 6 | 6 | 7 |
| Withdrew: Adverse event | 3 | 4 | 3 | 4 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 | 1 |
| Withdrew: Per investigator/sponsor/regulatory body | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 1 |
| Withdrew: Participant went out of town | 0 | 0 | 1 | 0 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. Least square (LS) mean percent change from Baseline to Week 12 was based on an analysis of covariance (ANCOVA) model with effects of treatment and triglyceride (TG) stratum and Baseline value as a covariate. Missing LDL-C values at Week 12 were imputed using the last observation carried forward (LOCF) procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) | -17.9 ± 2.17 | -25.0 ± 2.12 | -26.6 ± 2.16 | -2.1 ± 2.16 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and center and Baseline value as a covariate. Missing LDL-C values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Normal (TG<150 mg/dL) | -17.8 ± 2.92 | -21.9 ± 2.73 | -29.2 ± 2.72 | 0.3 ± 2.89 |
| Elevated (TG≥150 mg/dL) | -17.8 ± 3.21 | -28.1 ± 3.22 | -23.6 ± 3.37 | -4.5 ± 3.22 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing TG values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in TG | -15.1 ± 4.29 | -10.6 ± 4.16 | 1.1 ± 4.26 | -1.2 ± 4.29 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing HDL-C values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in High-Density Lipoprotein-Cholesterol (HDL-C) | 7.2 ± 2.22 | 0.9 ± 2.12 | 4.4 ± 2.16 | 2.4 ± 2.18 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing non-HDL-C values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Non-HDL-C | -17.4 ± 2.01 | -22.7 ± 1.95 | -23.0 ± 2.00 | -2.3 ± 2.00 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing TC values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Total Cholesterol (TC) | -11.5 ± 1.53 | -17.8 ± 1.50 | -17.1 ± 1.53 | -1.4 ± 1.53 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing ApoB values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Apolipoprotein B (ApoB) | -14.6 ± 1.83 | -18.4 ± 1.82 | -22.1 ± 1.84 | -0.9 ± 1.83 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing ApoAI values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Apolipoprotein AI (ApoAI) | 2.9 ± 1.96 | -2.7 ± 1.95 | 0.0 ± 1.97 | -3.1 ± 1.95 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing Lipoprotein (a) values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Lipoprotein (a) | 0.3 ± 5.20 | 7.6 ± 5.20 | 16.2 ± 5.27 | -2.7 ± 5.22 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing FFA values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Free Fatty Acids (FFA) | 2.5 ± 6.15 | -14.4 ± 6.08 | 5.3 ± 6.34 | 3.6 ± 6.09 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the value from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing hsCRP values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (hsCRP) | 18.4 ± 42.45 | 57.0 ± 42.44 | 48.0 ± 43.24 | 86.6 ± 42.45 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Total LDL Particles | -14.8 ± 2.26 | -16.3 ± 2.23 | -20.7 ± 2.34 | 1.9 ± 2.22 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).
| Percent Change | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Total HDL Particles | 5.7 ± 1.78 | 3.6 ± 1.74 | 7.3 ± 1.84 | 0.4 ± 1.75 |
TEAEs were defined as adverse events (AEs) that began or worsened in severity after the first dose of study medication, occurring up to 30 days after the last dose of study medication.
| Participants | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 34 | 32 | 31 | 33 |
Clinical significance was determined by the investigator.
| Participants | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Physical Examination Findings | 2 | 2 | 0 | 2 |
Clinical importance was determined by the investigator.
| Participants | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Clinically Important Changes From Baseline in Vital Sign Values | 0 | 0 | 0 | 0 |
Clinical importance was determined by the investigator.
| Participants | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Clinically Important Changes From Baseline in Electrocardiogram Values | 0 | 0 | 0 | 0 |
Laboratory abnormalities are laboratory values that are outside the normal range.
| Participants | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Alanine aminotransferase | 4 | 3 | 3 | 4 |
| Aspartate aminotransferase | 5 | 6 | 8 | 2 |
| Creatine kinase | 12 | 8 | 3 | 5 |
| Creatinine | 1 | 0 | 1 | 0 |
| Total bilirubin | 1 | 1 | 0 | 1 |
| Uric acid | 6 | 8 | 6 | 3 |
| Hemoglobin | 5 | 8 | 4 | 2 |
| Leukocytes | 3 | 2 | 1 | 1 |
Collected over up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ETC-1002 40 mg | 0/45 (0%) | 0/45 (0%) | 15/45 (33.3%) |
| ETC-1002 80 mg | 0/44 (0%) | 0/44 (0%) | 18/44 (40.9%) |
| ETC-1002 120 mg | 0/44 (0%) | 0/44 (0%) | 17/44 (38.6%) |
| Placebo | 0/44 (0%) | 1/44 (2.3%) | 17/44 (38.6%) |
| Event | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| Chest PainGeneral disorders | 0/45 | 0/44 | 0/44 | 1/44 |
| Event | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 5/45 | 5/44 | 7/44 | 4/44 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/45 | 2/44 | 1/44 | 6/44 |
| NauseaGastrointestinal disorders | 3/45 | 3/44 | 4/44 | 2/44 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 0/45 | 0/44 | 4/44 | 1/44 |
| Urinary Tract InfectionInfections and infestations | 4/45 | 1/44 | 0/44 | 1/44 |
| DiarrhoeaGastrointestinal disorders | 3/45 | 3/44 | 1/44 | 3/44 |
| BronchitisInfections and infestations | 0/45 | 3/44 | 1/44 | 1/44 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/45 | 2/44 | 3/44 | 0/44 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/45 | 3/44 | 1/44 | 1/44 |
| FatigueGeneral disorders | 3/45 | 1/44 | 1/44 | 1/44 |
Baseline data are reported for members of the Safety Population, comprised of all randomized participants who received at least 1 dose of study medication.
| Age, Continuous(Years) | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 58.4 ± 8.66 | 58.8 ± 9.00 | 56.7 ± 9.92 | 55.5 ± 10.40 | 57.3 ± 9.52 |
| Sex: Female, Male(Participants) | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 26 | 21 | 19 | 13 | 79 |
| Male | 19 | 23 | 25 | 31 | 98 |
| Race (NIH/OMB)(Participants) | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 | 2 |
| Black or African American | 7 | 7 | 2 | 6 | 22 |
| White | 38 | 36 | 41 | 37 | 152 |
| More than one race | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Calculated Low-density Lipoprotein Cholesterol (LDL-C)(milligrams per deciliter (mg/dL)) | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 163.1 ± 24.88 | 170.2 ± 26.23 | 165.0 ± 23.08 | 167.4 ± 22.03 | 166.4 ± 24.05 |
| LDL-C by Triglyceride (TG) Stratum(mg/dL) | ETC-1002 40 mg | ETC-1002 80 mg | ETC-1002 120 mg | Placebo | Total |
|---|---|---|---|---|---|
| Normal Stratum, TG<150 mg/dL | 153.8 ± 22.06 | 164.6 ± 25.36 | 160.2 ± 17.30 | 166.6 ± 17.87 | 161.2 ± 21.15 |
| Elevated Stratum, TG≥150 mg/dL | 172.9 ± 24.35 | 175.7 ± 26.46 | 169.8 ± 27.25 | 168.2 ± 25.94 | 171.7 ± 25.73 |
The record gives a start of Dec 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2021, 9 years 6 months after primary completion. A results delay was requested in Aug 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid